Pediatric patients with refractory central nervous system tumors: Experiences of a clinical trial combining bevacizumab and temsirolimus

Anticancer Research

Volumn 34, Issue 4, 2014, Pages 1939-1946

  Piha Paul, Sarina A ^a   Shin, Sang Joon ^a   Vats, Tribhawan ^a   Guha Thakurta, Nandita ^a   Aaron, Joann ^a   Rytting, Michael ^a   Kleinerman, Eugenie ^a   Kurzrock, Razelle ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Bevacizumab; CNS tumors; Pediatric; Temsirolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHYPERTENSIVE AGENT; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; DEXAMETHASONE; TEMSIROLIMUS; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; RAPAMYCIN;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPENDYMOMA; GLIOBLASTOMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PONTINE GLIOMA; SIDE EFFECT; SKIN TOXICITY; SKIN ULCER; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR REGRESSION; WEIGHT REDUCTION; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT; BRAIN TUMOR; CNS TUMORS; NUCLEAR MAGNETIC RESONANCE IMAGING; PEDIATRIC; PRESCHOOL CHILD; TREATMENT OUTCOME;

BEVACIZUMAB; CNS TUMORS; PEDIATRIC; TEMSIROLIMUS;

ADOLESCENT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; HUMANS; MAGNETIC RESONANCE IMAGING; PROTEIN KINASE INHIBITORS; SIROLIMUS; TREATMENT OUTCOME;

EID: 84902246311     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Linabery AM and Ross JA: Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer 112: 416-432, 2008.
2. Grill J, Puget S, Andreiuolo F, Philippe C, MacConaill L and Kieran MW: Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer 58: 489-491, 2012.
3. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN and Edwards BK: Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101: 3-27, 2004.
4. Miletic H, Niclou SP, Johansson M and Bjerkvig R: Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin Ther Targets 13: 455-468, 2009.
5. Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl 3): 4-10, 2005.
6. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307: 58-62, 2005.
7. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX and Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434, 2003.
8. Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027, 2005.
9. Knobbe CB, Merlo A and Reifenberger G: Pten signaling in gliomas. Neuro Oncol 4: 196-211, 2002.
10. Wang JY, Del Valle L, Gordon J, Rubini M, Romano G, Croul S, Peruzzi F, Khalili K and Reiss K: Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas. Oncogene 20: 3857-3868, 2001.
11. Gilbertson RJ, Clifford SC, MacMeekin W, Meekin W, Wright C, Perry RH, Kelly P, Pearson AD and Lunec J: Expression of the ErbB-neuregulin signaling network during human cerebellar development: Implications for the biology of medulloblastoma. Cancer Res 58: 3932-3941, 1998.
12. Elenius K, Choi CJ, Paul S, Santiestevan E, Nishi E and Klagsbrun M: Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 18: 2607-2615, 1999.
13. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, Gusella JF and Ramesh V: NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 29: 4250-4261, 2009.
14. Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J and Prados MD: Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzymeinducing antiepileptic drugs. Invest New Drugs 22: 427-435, 2004.
15. Geoerger B, Kerr K, Tang CB, Fung KM, Powell B, Sutton LN, Phillips PC and Janss AJ: Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 61: 1527-1532, 2001.
16. Pantuck AJ, Zeng G, Belldegrun AS and Figlin RA: Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 9: 4641-4652, 2003.
17. Piha-Paul S "An Innovative Phase I Trial Design Allowing for the Identification of Multiple Potential Maximum Tolerated Doses with Combination Therapy of Targeted Agents". UT GSBS Dissertations and Theses. Paper 72. http://digitalcommons.library.tmc.edu/utgsbs-dissertations/72, 2010.
18. Louis DN OH, Wiestler OD and Cavenee WK: Classification of Tumours of the Nervous System. IARC Press, Lyon, France, 2007.
19. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. Bethesda, MD, 2003.
20. Macdonald DR, Cascino TL, Schold SC Jr. and Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990.
21. Lansky SB, List MA, Lansky LL, Ritter-Sterr C and Miller DR: The measurement of performance in childhood cancer patients. Cancer 60: 1651-1656, 1987.
22. Parekh C, Jubran R, Erdreich-Epstein A, Panigrahy A, Bluml S, Finlay J and Dhall G: Treatment of children with recurrent highgrade gliomas with a bevacizumab containing regimen. J Neurooncol 103: 673-680, 2011.
23. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH and Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25: 4722-4729, 2007.
24. Verheul HM andPinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7:475-485, 2007.
25. Drappatz J, Schiff D, Kesari S, Norden AD and Wen PY: Medical management of brain tumor patients. Neurol Clin 25: 1035-1071, ix, 2007.
26. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D and Ravaud A: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456, 2008.
27. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L and Motzer RJ: Temsirolimus, interferon alpha, or both for advanced renal cell carcinoma. N Engl J Med 356: 2271-2281, 2007.
28. Altomare I, Bendell JC, Bullock KE, Uronis HE, Morse MA, Hsu SD, Zafar SY, Blobe GC, Pang H, Honeycutt W, Sutton L and Hurwitz HI: A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist 16: 1131-1137, 2011.
29. Spunt SL, Grupp SA, Vik TA, Santana VM, Greenblatt DJ, Clancy J, Berkenblit A, Krygowski M, Ananthakrishnan R, Boni JP and Gilbertson RJ: Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J Clin Oncol 29: 2933-2940, 2011.
30. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G and Sherman ML: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22: 909-918, 2004.
31. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J and Prados MD: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23: 357-361, 2005.
32. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ and Abraham RT: Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol 22: 7004-7014, 2002.
33. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW and Semenza GL: Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545, 2000.
34. George DJ andKaelin WG Jr.: The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 349: 419-421, 2003.